Amylyx Pharmaceuticals, Inc.
AMLX
Peringkat dalam Saham
#4525
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Harga Saham
$26.87
Kapitalisasi Pasar
$3.37B
Perubahan (1 hari)
2.01%
Perubahan (1 tahun)
79.73%
Negara
US
Perdagangan Amylyx Pharmaceuticals, Inc. (AMLX)
Kategori
Healthcare
Riwayat dividen untuk Amylyx Pharmaceuticals, Inc. (AMLX)
Saham Amylyx Pharmaceuticals, Inc. (simbol: AMLX) telah membayar total 3 dividen.
Total semua dividen (disesuaikan dengan stock split): $1.02
Imbal hasil dividen (TTM): 0
Total semua dividen (disesuaikan dengan stock split): $1.02
Imbal hasil dividen (TTM): 0
Pembayaran dividen untuk Amylyx Pharmaceuticals, Inc. (AMLX) dari 2017 hingga 2026
Pembayaran dividen tahunan
| Tahun | Dividen (disesuaikan dengan stock split) | Mengubah |
|---|---|---|
| 2026 (TTM) | $0.42 | 0.00% |
| 2018 | $0.42 | -30.00% |
| 2017 | $0.6 | 0.00% |
Daftar semua pembayaran dividen
| Tahun | Dividen | Mengubah |
|---|---|---|
| 2026 (TTM) | $0.42 | 0.00% |
| 2018 | $0.42 | -30.00% |
| 2017 | $0.6 | 0.00% |
Pembayaran dividen untuk perusahaan sejenis atau pesaing
| Perusahaan | Jumlah pembayaran dividen | Negara |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 64.00% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
